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The autoimmune process that destroys the insulin-producing pancreatic 
 
 
 
 cells in type 1 
diabetes (T1D) is targeted at insulin and its precursor, proinsulin. T cells that recognize the 
proximal A-chain of human insulin were identified recently in the pancreatic lymph nodes of 
subjects who had T1D. To investigate the specificity of proinsulin-specific T cells in T1D, we 
isolated human CD4
 
 
 
 T cell clones to proinsulin from the blood of a donor who had T1D. The 
clones recognized a naturally processed, HLA DR4–restricted epitope within the first 13 
amino acids of the A-chain (A1–13) of human insulin. T cell recognition was dependent on 
the formation of a vicinal disulfide bond between adjacent cysteine residues at A6 and A7, 
which did not alter binding of the peptide to HLA DR4. CD4
 
 
 
 T cell clones that recognized 
this epitope were isolated from an HLA DR4
 
 
 
 child with autoantibodies to insulin, and 
therefore, at risk for T1D, but not from two healthy HLA DR4
 
 
 
 donors. We define for the 
first time a novel posttranslational modification that is required for T cell recognition of the 
insulin A-chain in T1D.
 
Type 1 diabetes (T1D) is an autoimmune dis-
ease in which insulin-producing pancreatic 
 
 
 
cells are destroyed by autoreactive T cells (1).
Many genetic loci have been associated with
T1D, but the highest risk is associated with
the HLA complex, specifically with the class
II HLA haplotypes, DR3-DQ2 and DR4-
DQ8 (2, 3). Class II HLA molecules present
peptide antigen to CD4
 
 
 
 T cells, which under-
lines the role of CD4
 
 
 
 T cells in the pathogenesis
of T1D. Several lines of evidence implicate
proinsulin as a target autoantigen in T cell–
mediated 
 
 
 
 cell destruction in humans and the
NOD mouse model of T1D (4). Proinsulin is
the major product of 
 
 
 
 cells and, with the
possible exception of rare self-antigen–expressing
cells in lymphoid tissues (5), is the only known
T1D autoantigen that is expressed exclusively
in 
 
 
 
 cells. Autoantibodies to (pro)insulin are a
strong risk factor for the development of T1D
(6). The T1D susceptibility locus IDDM2
maps to a variable number of tandem repeats
(VNTRs) upstream of the insulin gene (7); the
long class III VNTR allele is associated with
higher levels of proinsulin mRNA in the thymus
and decreased susceptibility to T1D (8, 9).
NOD mice that transgenically express proinsulin
under the control of an MHC class II promoter
are protected from diabetes (10, 11). NOD
mice with targeted disruptions of the proinsulin
I and II genes have a decreased (12) and increased
(13) incidence of diabetes, respectively. Further-
more, diabetes did not develop in NOD mice
that expressed a mutated proinsulin I (Y to A
at B16) (14). Recently, it was reported that
HLA DR4–restricted, CD4
 
 
 
 T cells that react
to the first 15 amino acids of the insulin A-chain
make up a large proportion of T cells from the
pancreatic lymph nodes of two subjects with
who had T1D, but not from three healthy
donors (15). However, the nature of the epi-
tope was not defined.
There is increasing evidence, mainly from
animal models, that pathogenic T cells in au-
toimmune disease recognize epitopes that are
formed by posttranslational modification of
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self-antigens (16). To our knowledge, there is only one re-
port of human CD4
 
 
 
 T cells that recognize an epitope
formed by posttranslational modification. Subjects who have
rheumatoid arthritis have T cells that react to a glycosylated
collagen epitope (17). Here, we sought to define the speci-
ficity of proinsulin-specific CD4
 
 
 
 T cells in T1D. We show
for the first time that T cell recognition of the first 13 amino
acids of human insulin A-chain requires posttranslational
modification of adjacent cysteine residues at A6 and A7.
 
RESULTS AND DISCUSSION
Identification of the insulin A-chain 1–13 epitope
 
17 proinsulin-specific CD4
 
 
 
 T cell clones were isolated
from the blood of a donor who had established T1D (18).
The insulin A1–13 epitope was identified using an overlap-
ping panel of 15-mer peptides. First, the clones were cul-
tured with eight peptide pools, each containing three to four
peptides, and covering the entire sequence of proinsulin. 5
of 17 clones recognized a peptide within pool 8 (Fig. 1 A);
four were studied further. The three peptides in pool 8 were
tested separately, and a single peptide comprising the last two
amino acids of the C-peptide and the first 13 amino acids of
the A-chain of insulin (KRGIVEQCCTSICSL) stimulated
all four clones (Fig. 1 B). Moreover, individual peptides
comprising the first 13 and 15 amino acids of the A-chain of
insulin (Table S2, available at http://www.jem.org/cgi/
content/full/jem.20051251/DC1) also stimulated the clones
with equivalent dose response (Fig. 1 C). Furthermore, insu-
lin and proinsulin stimulated the clones equally. The re-
sponse to clinical grade recombinant insulin was HLA DR
dependent (Fig. 1 D). Hence, the clones recognize a mini-
mal epitope comprising the first 13 amino acids of the
Figure 1. Identification of the A-chain 1–13 epitope. (A) Preliminary 
epitope mapping. Peptides, 15-mers shifted by three amino acids, comprising 
proinsulin, were grouped into eight pools of three to four peptides (5  g/
ml each), or proinsulin (10  g/ml) were included as indicated. Mean of 
triplicates   SEM is shown. (B) Fine epitope mapping. Three peptides from 
pool 8 were tested separately. (C) Responses to insulin and A-chain peptides. 
Insulin (open circles) and proinsulin (filled circles) were titrated from 1  M 
to 0.1 nM. Peptides KR-A1-13 (filled triangles), A1–13 (filled diamonds), 
and A1-15 (filled squares) were titrated from 10  M to 0.1 nM. Other 
conditions were the same as for A. (D) Responses to insulin. T cell clones 
were cultured with proinsulin (10  g/ml), insulin (10  g/ml), or without 
antigen (no antigen). Anti-HLA DR mAb (5  g/ml) was included as indicated. 
(E) Responses to islet lysate. T cell clones were cultured with dilutions of 
human islet lysate (filled circles), spleen lysate (open circles), insulin (10 
 g/ml; filled square), or without antigen (open square). 
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A-chain of human insulin. To confirm that the T cell clones
recognized an epitope that was derived from native human
insulin, their response to human islet lysate was tested. The
clones proliferated in a dose-dependent manner to islet, but
not spleen, lysate from the same donor (Fig. 1 E). Hence, the
clones recognized a naturally processed and presented epitope
in the first 13 amino acids of the A-chain of human insulin.
 
Mapping the fine HLA restriction of the insulin 
A1–13 epitope
 
Experiments with HLA isotype–specific antibodies showed
that proliferation of all clones was blocked by anti-HLA
DR (L243) mAb (Fig. 2 A). Next, EBV-transformed B cells
from a patient who had bare lymphocyte syndrome (BLS)
that were transfected with different HLA-
 
 
 
 genes were used
as APCs. Cells that were transfected with DRB1
 
*
 
0401,
DRB1
 
*
 
0404, or DRB1
 
*
 
0405 presented the A1–13 epitope,
whereas cells that were transfected with DRB4
 
*
 
0101
(DR53), DQB1
 
*
 
0201 (DQ2), or DQB1
 
*
 
0302 (DQ8) did
not (Fig. 2 B). Hence, the A1–13 epitope can be presented
by HLA DRB1
 
*
 
0401, 0404, and 0405. It is well established
that HLA DR4 confers susceptibility to T1D (2, 3). HLA
DR4 has been associated with high-affinity and high-titer
insulin autoantibodies (6) that typically are found in young
individuals who are at high risk for developing T1D. Achen-
bach
 
 
 
et al. (6) reported that these antibodies bound to the
middle of the A-chain (A8-10/13), a region that is contained
within the A1–13 CD4
 
 
 
 T cell epitope described here. An-
tibodies can increase antigen uptake and processing (19).
Therefore, insulin autoantibodies that bind to the A-chain of
insulin could enhance the presentation of the A1–13 epitope
to CD4
 
 
 
 T cells, and, in turn, augment autoantibody pro-
duction and explain, in part, the high titers of insulin anti-
bodies in HLA DR4
 
 
 
 subjects.
 
The requirement for cysteine residues in T cell recognition
 
The requirement for the three cysteines in the A1–13
epitope was determined by testing peptides in which serine
was substituted for each cysteine (Table S2). Replacing ei-
ther of the adjacent cysteines at A6 or A7 with serine com-
pletely abolished the peptide’s capacity to stimulate the T
Figure 2. The response to insulin A1-13 is HLA DR4 restricted. 
(A) Coarse HLA restriction. Antibodies specific for HLA DR (L243), HLA DQ 
(SPV-L3), or HLA DP (B7/21) were added to a final concentration of 5  g/ml. 
(B) Fine HLA restriction. Insulin-specific T cells were incubated with irradiated, 
HLA-transfected BLS cells pulsed with 100  M KR-A1-13 peptide (filled 
bars) or solvent (open bars). Proliferation of the BLS cells alone after irradiation 
(1,000–5,000 cpm) was subtracted, and results are expressed as net 
3H-thymidine incorporation ( cpm). Mean   SEM of triplicates is shown.
Figure 3. Oxidized cysteine at A6 and A7, but not antigen processing, 
is required to elicit responses of T cell clones. (A) Serine for cysteine 
substitutions. Insulin-specific T cell clones were cultured in the presence 
of 50—0.05  M peptide (see Table S2). KR-A1-13 peptide (open squares), 
S-6 (filled triangles), S-7 (filled diamonds), S-11 (filled circles), or murine 
KR-A1-13 (open circles). (B) Effect of TCEP on responses to the A1-13 
epitope. S-11 peptide (1  M) was treated with TCEP at the concentrations 
shown (filled squares). Controls were comprised of either PHA (1.25  g/ml) 
and IL-2 (2.5 U/ml; filled circles) or were without antigen (open squares). 
(C) Effect of APC fixation. HLA-DRB1*0404–transfected BLS cells were 
fixed cultured with RP-HPLC purified S-11 peptide and T cell clones (filled 
circles), or with unfixed BLS cells (open circles). Fixed cells with solvent 
alone (filled squares), or unfixed cells with solvent alone (open squares) 
were included. The mean   SEM of triplicate wells is shown. 
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cell clones (Fig. 3 A), whereas replacing the A11 cysteine
with serine had no effect. The analogue peptide (S-11), with
serine substituted for cysteine at position A11, was used in
subsequent experiments. A peptide corresponding to the se-
quence of mouse insulin A1-13 (KRGIVDQCCTSICSL)
was 
 
 
 
10-fold less potent than was the human homologue.
The absolute requirement of the adjacent cysteines at A6 and
A7 for T cell recognition suggested that the epitope recog-
nized by the T cell clones may require oxidative modifica-
tion of the cysteines. To evaluate this possibility, the S-11
peptide was exposed to the disulfide-reducing agent, TCEP
(Tris (2-carboxyethyl) phosphine hydrochloride). Reduction
abolished the ability of S-11 to stimulate the clones (Fig. 3
B), which was consistent with oxidation-dependent modifi-
cation of the adjacent cysteines required for T cell recogni-
tion. To determine if modification of the cysteines occurred
spontaneously in culture medium or during antigen process-
ing, we tested the capacity of paraformaldehyde-fixed and
unfixed APCs to present the peptide to the T cell clones
(Fig. 3 C). Fixation did not alter T cell reactivity. Therefore,
we concluded that T cell recognition of the A1–13 epitope
depended on the presence of oxidized cysteine residues at
A6 and A7, a modification that did not require antigen up-
take and intracellular processing.
 
Analysis of oxidized cysteine residues at A6 and A7
 
To determine the nature of the oxidized cysteine residues,
the S-11 peptide was incubated in culture medium and the
components were separated by reversed-phase (RP)–HPLC.
A single fraction stimulated proliferation of the T cell clones
(Fig. 4 A). No fractions stimulated proliferation when the
S-6 peptide was used in similar experiments (unpublished
data). Analysis of the active fraction by mass spectrometry
(MS) showed that it contained a single species that was 2 Dl-
tons smaller than predicted for the parental S-11 peptide
(Fig. 4, B–E). Tandem MS/MS analysis revealed that this
Figure 4. The A1–13 epitope contains a vicinal disulfide bond 
between cysteine A6 and A7. (A) Isolation of the modified peptide. The 
absorbance at 214 nm (line) and proliferation of an insulin-specific T cell 
clone (bars) in response to each fraction (1/400 dilution) is shown. 
MALDI-QTOF mass spectrometry was used to analyze the parental S-11 
peptide at low (B) and high (C) resolution. The active fraction (fraction 7) 
from the serum-modification experiment at low (D) and high (E) 
resolution is shown. 
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loss of 2 Dltons arose at the adjacent cysteines (Table S3,
available at http://www.jem.org/cgi/content/full/jem.
20051251/DC1). This indicated that the epitope contained
a vicinal disulfide bond (i.e., a disulfide bond between the
adjacent A6 and A7 cysteines). This is the only modification
that would eliminate two protons to result in a 2-Dlton de-
crease in mass. The vicinal disulfide bond formed within
minutes, and treatment of the modified S-11 peptide with
dithiothreitol reduced the vicinal disulfide bond and in-
creased the mass by 2 Dltons (unpublished data). Using
MS, we found no evidence of cysteinylation, sulphation, or
S-nitrosylation of these residues. There was no evidence, by
MS, for a vicinal disulfide bond in the recombinant proinsu-
lin that was used to stimulate T cells.
Previous studies suggested that the oxidation state of in-
sulin-derived peptides may play a role in immunogenicity
(20). The first 14 amino acids of the A-chain of bovine insu-
lin (GIVEQCCASVCSLY) are recognized by murine (20)
and human T cells (21) after immunization. Nonetheless, T
cell epitopes containing vicinal disulfide bonds have not
been reported previously. The vicinal disulfide bond be-
tween A6 and A7 occurs during refolding of insulin in vitro
(22). This suggests that the nonnative vicinal disulfide bond
that formed between cysteines A6 and A7 predominates un-
der oxidatively permissive conditions in vitro for the syn-
thetic peptide, and after presentation of exogenous recombi-
nant and native (pro)insulin.
 
Binding and modeling of modified and unmodified insulin 
A1-13 peptide to HLA DR4
 
The S-11 peptide containing a vicinal disulfide bond
(KRGIVEQC-CTSISSL) and the serine-substituted homo-
logue (KRGIVEQSSTSISSL) had similar binding affinities for
HLA DRB1
 
*
 
0404 (0.024 
 
 
 
M and 0.030 
 
 
 
M, respectively,
Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20051251/DC1). The serine-substituted peptide was
used to avoid spontaneous oxidation of cysteine during the
HLA binding assay. Both peptides also bound equally well to
HLA DRB1
 
*
 
0401 (unpublished data). Thus, the vicinal disul-
fide bond did not alter binding to HLA DR4. The binding
register of the insulin A1–13 epitope was determined to be the
core nonamer VEQCCTSIS, using the ProPred algorithm
(23). The formation of a vicinal disulfide bond between
cysteine residues at A6 and A7 impacts on the conformation
and solvent accessibility of the central portion of the epitope
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20051251/DC1). The vicinal disulfide bond creates a
structure that is unable to be mimicked by other naturally oc-
curring amino acids; this explains the failure of serine substi-
tution to stimulate, even in part, the T cell clones.
 
Analysis of T cell clones from an individual at risk for T1D 
and healthy donors
 
To determine whether T cells specific for the cysteine-mod-
ified epitope are present before the onset of clinical T1D, we
isolated 11 proinsulin-specific CD4
 
 
 
 T cell clones from an
asymptomatic HLA DRB1
 
*
 
0404
 
 
 
 12-yr-old with autoanti-
bodies to insulin. Three of the clones responded to proinsu-
lin, insulin, KR-A1-13, and S-11 peptides, but not to S-6 or
S-7 peptides (Fig. 5 A). They recognized S-11 peptide in as-
sociation with HLA DRB1
 
*
 
0404-0405 (Fig. 5 B). Further-
more, the RP-HPLC fraction containing the A1-13 epitope
with the vicinal disulfide bond stimulated these clones (Fig.
Figure 5. T cell clones from a donor at high risk for T1D recognize 
the A1–13 epitope. (A) Isolation of T cell clones. T cell clones were cultured 
with proinsulin (10  g/ml), insulin (10  g/ml), or the KR-A1-13, S-6, S-7, or 
S-11 peptides (10  M each), or without antigen. (B) HLA restriction. Irradiated 
BLS cells that were transfected with the HLA genes shown were pulsed with 
100  M S-11 peptide (filled bars) or solvent alone (open bars). The results are 
expressed as net cpm proliferation ( cpm) after subtracting the proliferation 
of BLS cells alone. (C) Peptide modification in culture medium. Fixed BLS 
cells that were transfected with HLA DRB1*0404 were cultured with 
RP-HPLC fractions from Fig. 4. MS analysis of fraction 7 is shown in Fig. 4, D 
and E. Each point is the mean   SEM of triplicate wells. 
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5 C). In contrast, none of the 13 proinsulin-specific CD4
 
 
 
 T
cell clones that were isolated from two healthy HLA DR4
 
 
 
donors (6 and 7 clones, respectively) proliferated in response
to KR-A1-13 peptide (unpublished data). Hence, T cells
specific for the A1–13 epitope were not detected in healthy
subjects, but were present in the blood of an individual with
insulin autoantibodies.
Kent et al. (15) recently reported that CD4
 
 
 
 T cells
that are specific for the first 15 amino acids of the A-chain
of insulin were overrepresented in the pancreatic lymph
nodes from two HLA DR4
 
 
 
 diabetic subjects, but not in
the pancreatic lymph nodes from one HLA DR4
 
 
 
 
 
subject
and two other control subjects. We isolated proinsulin-
specific CD4
 
 
 
 T cell clones from blood, the only tissue
that is available for routine analysis in humans. T cell
clones that recognized the first 13 amino acids of the
A-chain of insulin also responded to islet cell lysate, which
demonstrated that the A-chain epitope is naturally pro-
cessed and presented. The epitope requires a vicinal disul-
fide bond between cysteines A6 and A7, which is essential
for T cell recognition, but not for binding to HLA DR4.
T cell responses to A1–13 were not a result of injecting in-
sulin, because CD4
 
 
 
 T cells that recognized the A1–13
epitope were isolated from a donor who had never in-
jected insulin, but had evidence of insulin autoimmunity.
Our findings extend to T1D the paradigm that autoim-
mune responses can target epitopes that are formed by
posttranslational modification.
 
MATERIALS AND METHODS
 
Human subjects and peripheral blood mononuclear cell isolation.
 
Blood was obtained by venepuncture with informed consent and ethics
committee approval. The HLA typing and clinical status of each donor are
shown in Table S1 (available at http://www.jem.org/cgi/content/full/
jem.20051251/DC1). PBMCs were cultured in IMDM (GIBCO BRL)
supplemented with 5% pooled male human serum, 2 mM glutamine
(Glutamax; GIBCO BRL), 5 
 
 
 
 10
 
 
 
5 
 
M 2-mercaptoethanol (Sigma-Aldrich),
penicillin (100 U/ml), streptomycin (100 
 
 
 
g/ml; GIBCO BRL), and 100
 
 
 
M nonessential amino acids (GIBCO BRL), hereafter referred to as cul-
ture medium. Islets and spleen samples were obtained from the Tom Man-
del Islet Transplant Program with the approval of the St Vincent’s Hospital
Human Ethics Committee.
 
Antigens.
 
Synthetic peptides were purchased from Mimotopes, and re-
constituted to 5 mM in 0.5% acetic acid, 40% acetonitrile in water. A li-
brary of 15-mer peptides overlapping by 12 amino acids, comprising the
entire sequence of human proinsulin, was used for initial epitope-mapping
experiments. All single peptides were 
 
 
 
80% pure, and are summarized in
Table S2. The vicinal disulfide bond (represented by C-C) in peptide
S-11 was generated by incubating peptide in serum-free IMDM for 1 h.
Modified peptide was purified by RP-HPLC, and analyzed as described
below. Recombinant human proinsulin was produced in-house using a
published protocol (24), and was shown to be folded correctly and free of
endotoxin. Human islet lysate was prepared from 
 
 
 
100 hand-picked islets
resuspended in 0.5 ml of serum-free IMDM, then frozen, thawed, and so-
licited three times. Spleen lysate from the same donor was prepared similarly.
 
CFSE staining and T cell cloning.
 
Staining with the dye, CFSE (5,6-
carboxylfluorescein diacetate succinimidyl ester; Invitrogen), T cell cloning,
and testing for antigen specificity was performed as described (18).
 
3
 
H-thymidine incorporation assays.
 
Assays were performed in 96-well
round-bottom plates in 5% pooled human serum/IMDM. APCs were (a) ir-
radiated (20 Gy) autologous or HLA-matched PBMCs (fresh or thawed); (b)
HLA-typed EBV-transformed B cell lines from the 9th International HLA
Typing Workshop; or (c) EBV-transformed B cells, from a donor who had
bare lymphocyte syndrome (BLS), that were transfected with different HLA
genes. EBV lines were irradiated at 50 Gy. In some experiments, APCs were
fixed with 1% paraformaldehyde for 20 min at room temperature, and
washed twice in PBS and once in culture medium before use in proliferation
assays. In other experiments, freshly prepared TCEP (Tris (2-carboxyethyl)
phosphine hydrochloride (Pierce Chemical Co.) was added to the antigen
solution, before dilution by medium and addition of APCs and T cells to the
final concentration shown in the figures. For all experiments, T cells and
APCs were cultured in triplicate in 96-well round-bottom plates. After 2 d,
 
3
 
H-thymidine (0.5 
 
 
 
Ci/well) was added for 18 h, after which the cells were
harvested and incorporated radioactivity was measured by 
 
 
 
-scintillation
counting. Results are expressed as the mean 
 
 
 
 SEM of triplicate wells. All
experiments were done at least twice with at least two clones.
 
HPLC fractionation and mass spectrometry.
 
Modifications of KR-
A1-13 peptide in culture media were investigated after incubating 1.8 mg of
peptide with 1.8 ml of culture media for 1 h at 37
 
 
 
C. The incubate was
fractionated by RP-HPLC using an AKTA Basic HPLC equipped with a
multi-wavelength tunable UV detector and a Frac 950 fraction collector
(GE Healthcare). Proteins were separated on a Vydac C18 column (4.6
i.d.   250 mm, 300 Å pore size, 5- m nominal particle size), using a linear
gradient of buffer A (0.1% TFA) to 60% B (acetonitrile/0.09% TFA;
0.86%/min), at a flow rate of 1 ml/min. Fractions (500  l) were collected
and 1- l aliquots were mixed with 1  l of 2,5-dihydroxybenzoic acid (Ag-
ilent Technologies) and dried onto a sample stage for analysis by MALDI-
QqTOF MS (QSTAR pulsar i Applied Biosystems). Selected ions were
subjected to further analysis using MS/MS analysis. Fragment ions that were
generated in this way were assigned manually, based on the known se-
quence of the parental peptide and modified amino acid residues identified
within the sequence, as described (25).
Online supplemental material. Table S1 shows subjects defined by
their clinical status and HLA type. Table S2 shows that insulin A-chain pep-
tides used in this study. Table S3 shows the assignment of the b-series ions
from MS/MS analysis of S-11 peptide with a vicinal disulfide bond between
cysteines at A6 and A7. Fig. S1 shows HLA DR binding. Fig. S2 shows the
modeling of modified and unmodified insulin A1-13 peptide complexed
with HLA DR*0404. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20051251/DC1.
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